$16.82
0.372.25%
Últ. Act.: Oct 28, 4:46 PM
Aktis Oncology (AKTS) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Aktis Oncology (AKTS) publicó su última previsión de mayo 13, 2024 para Q4 2024. La compañía estimó ingresos en un rango de $7.92M - $8.33M para el período.
En comparación con la previsión anterior, Aktis Oncology reducido redujo su previsión de ingresos desde un rango anterior de $8.68M - $9.2M.
Aktis Oncology ha emitido 9 actualizaciones de orientación entre el noviembre 14, 2022 y el mayo 13, 2024. During this period, the company raised its outlook 4 times and lowered it 3 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q1 '25 | Q4 '24 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.43 | $-0.33 | $-0.11 | $-0.10 |
| Actual | $-0.44 | $-0.38 | $-0.04 | $-1.14 |
| Surprise | -2.33% | -15.2% | +63.6% | -1040.0% |
| Revenue | ||||
| Estimate | $2.5M | $2.1M | $7.3M | $8.0M |
| Actual | $3.4M | $3.2M | $9.0M | $5.9M |
| Surprise | +33.6% | +56.0% | +23.3% | -27.1% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.46 | $-0.48 | $-0.63 | $-0.63 |
| Revenue | ||||
| Consensus | $2.5M | $2.3M | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $-0.44 | $-0.43 | -2.33 % |
| Q1 | May 11, 2026 | $-0.38 | $-0.33 | -15.2 % |
| Q1 | Nov 14, 2024 | $-0.04 | $-0.11 | 63.6 % |
| Q4 | Oct 8, 2024 | $-1.14 | $-0.10 | -1040.0 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $3.38M | $2.53M | 33.6 % |
| Q1 | May 11, 2026 | $3.23M | $2.07M | 56.0 % |
| Q1 | Nov 14, 2024 | $9.03M | $7.32M | 23.3 % |
| Q4 | Oct 8, 2024 | $5.86M | $8.03M | -27.1 % |